<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bonus Biogroup — News on 6ix</title>
    <link>https://6ix.com/company/bonus-biogroup</link>
    <description>Latest news and press releases for Bonus Biogroup on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 14 Jul 2025 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bonus-biogroup" rel="self" type="application/rss+xml" />
    <item>
      <title>Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board</title>
      <link>https://6ix.com/company/bonus-biogroup/news/bonus-biogroup-appoints-renowned-cell-110000507</link>
      <guid isPermaLink="true">https://6ix.com/company/bonus-biogroup/news/bonus-biogroup-appoints-renowned-cell-110000507</guid>
      <pubDate>Mon, 14 Jul 2025 11:00:00 GMT</pubDate>
      <description>Appointment aims to reinforce Bonus Biogroup&apos;s leadership at a pivotal moment as the company advances toward Phase 3 clinical trials for its two flagship therapies: BonoFill and MesenCureHAIFA, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop novel tissue engineering and cell therapy solutions, announced the appointment of Professor of Cell Therapy and Pediat</description>
    </item>
    <item>
      <title>Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress</title>
      <link>https://6ix.com/company/bonus-biogroup/news/bonus-biogroup-announces-u-food-130000774</link>
      <guid isPermaLink="true">https://6ix.com/company/bonus-biogroup/news/bonus-biogroup-announces-u-food-130000774</guid>
      <pubDate>Thu, 20 Feb 2025 13:00:00 GMT</pubDate>
      <description>The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS) MesenCure&apos;s market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates TEL AVIV, Israel, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stromal ce</description>
    </item>
  </channel>
</rss>